Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Molecular data may refine outcome prediction in elderly AML patients

07 Jul 2020

Including molecular data, such as transcriptomic and mutational data, may help improve the prediction of outcomes in elderly patients with acute myeloid leukaemia (AML), a recent study has shown.

The study included 182 elderly AML patients (median age, 74 years; 50 percent female) who were intensively and palliatively being treated. Of the patients undergoing intensive chemotherapy, 59 percent reached complete remission, with median overall survival of 8.2 months. Each patient harboured a median of three somatic mutations.

The most commonly mutated gene in the cohort was the NPM1 gene, which saw mutations in 32 percent of the participants. This was followed by the TET2 (28 percent) and DNMT3A (25 percent) genes. The NPM1 gene (37 percent) was likewise the most commonly mutated gene in participant with de novo AML.

Multivariable Cox regression analysis found that mutations in the NPM1 gene were significantly correlated with better overall survival (OS; hazard ratio, 0.15, 95 percent confidence interval [CI], 0.06–0.35). The same was true for mutations in the IDH2 gene, while alterations in TP53 emerged as negative risk factors.

Similarly, NPM1 mutations correlated with better odds of achieving complete remission (CR; odds ratio, 0.46, 95 percent CI, 0.20–0.99), while TP53 mutations worsened the chances of CR.

In addition, transcriptomic data further improved outcome prediction. “When integrating the transcriptomic and mutational data with the aim to create an algorithm for CR prediction, two genes, ZBTB7A and EEPD1, added the most value to the molecular stratification,” the researchers said.

“Patients with high expression of both genes but without TP53 mutations formed a good-risk group with a CR rate of 97 percent.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.